Oak Asset Management LLC Has $3.78 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Oak Asset Management LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 2.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,165 shares of the company’s stock after selling 646 shares during the quarter. Johnson & Johnson accounts for approximately 1.4% of Oak Asset Management LLC’s holdings, making the stock its 20th biggest holding. Oak Asset Management LLC’s holdings in Johnson & Johnson were worth $3,784,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. One Capital Management LLC increased its holdings in Johnson & Johnson by 22.2% in the 2nd quarter. One Capital Management LLC now owns 66,330 shares of the company’s stock valued at $9,695,000 after buying an additional 12,034 shares during the period. Citizens Financial Group Inc. RI increased its holdings in Johnson & Johnson by 82.8% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 180,501 shares of the company’s stock valued at $26,382,000 after buying an additional 81,780 shares during the period. Wulff Hansen & CO. increased its holdings in Johnson & Johnson by 14,424.6% in the 2nd quarter. Wulff Hansen & CO. now owns 1,625,299 shares of the company’s stock valued at $237,554,000 after buying an additional 1,614,109 shares during the period. Luts & Greenleigh Group Inc. bought a new stake in Johnson & Johnson in the 2nd quarter valued at $1,131,000. Finally, Excalibur Management Corp increased its holdings in Johnson & Johnson by 1.6% in the 2nd quarter. Excalibur Management Corp now owns 40,514 shares of the company’s stock valued at $5,921,000 after buying an additional 629 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Bank of America reaffirmed a “neutral” rating and issued a $166.00 target price on shares of Johnson & Johnson in a report on Tuesday, December 10th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Morgan Stanley upped their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 7th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $174.71.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $144.68 on Wednesday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a market cap of $348.33 billion, a PE ratio of 20.94, a PEG ratio of 2.52 and a beta of 0.51. The company’s 50-day moving average is $149.12 and its two-hundred day moving average is $156.09.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the prior year, the company posted $2.66 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.43%. Johnson & Johnson’s payout ratio is presently 71.78%.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.